The global lung cancer diagnostics market is projected to register a substantial CAGR of 14.2% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030
Market Segmentation:
Global Lung Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales), Country (U.S., Canada, Mexico, Germany, France, U.K, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, Rest of the Middle East and Africa) Industry Trends and Forecast to 2030.
Some of the major factors contributing to the growth of the global lung cancer diagnostics market are:
Increase in research in the field of lung cancer diagnosis and development
Rise in prevalence and incidence of lung cancer in the world
Market Players:
Some of the major players operating in the global lung cancer diagnostics market are:
F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific Inc.
Abbott
Quest Diagnostics Incorporated
Biodesix
Amoy Diagnostics Co., Ltd.
Bio-Rad Laboratories, Inc.
Biocartis
Boditech Med Inc.
Danaher
Vela Diagnostics
DiaSorin S.p.A.
Exact Sciences UK, Ltd. (a subsidiary of Exact Science Corporation)
20/20 Gene Systems
Guardant Health, Inc.
Inivata Ltd.
LalPathLabs.com
LungLife AI, Inc.
MedGenome
Myriad Genetics, Inc.
NeoGenomics Laboratories
NanoString
Nanoentek
Oncocyte Corporation
PerkinElmer Inc.
PlexBio
QIAGEN
Siemens Healthcare GmbH
Veracyte, Inc.
TABLE OF CONTENTS
1 INTRODUCTION 53
- 1.1 OBJECTIVES OF THE STUDY 53
- 1.2 MARKET DEFINITION 53
- 1.3 OVERVIEW OF GLOBAL LUNG CANCER DIAGNOSTICS MARKET 53
- 1.4 LIMITATIONS 55
- 1.5 MARKETS COVERED 55
2 MARKET SEGMENTATION 58
- 2.1 MARKETS COVERED 58
- 2.2 GEOGRAPHICAL SCOPE 59
- 2.3 YEARS CONSIDERED FOR THE STUDY 60
- 2.4 CURRENCY AND PRICING 60
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 61
- 2.6 MULTIVARIATE MODELLING 64
- 2.7 PRODUCT TYPE LIFELINE CURVE 64
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 66
- 2.9 DBMR MARKET POSITION GRID 67
- 2.10 MARKET TESTING TYPE COVERAGE GRID 69
- 2.11 VENDOR SHARE ANALYSIS 70
- 2.12 SECONDARY SOURCES 71
- 2.13 ASSUMPTIONS 71
3 EXECUTIVE SUMMARY 72
4 PREMIUM INSIGHTS 75
- 4.1 PORTER'S FIVE FORCES 78
- 4.2 PESTEL ANALYSIS 79
- 4.3 INDUSTRY INSIGHTS 80
5 EPIDERMIOLOGY 81
6 REGULATIONS 82
7 MARKET OVERVIEW 85
- 7.1 DRIVERS 87
- 7.1.1 UNMET NEED FOR NON-INVASIVE, ACCURATE, AND RELIABLE DIAGNOSTIC TESTS FOR EARLIER CANCER DETECTION 87
- 7.1.2 INCREASING EARLY DIAGNOSIS OF LUNGS CANCER 88
- 7.1.3 INCREASING CASES OF LUNG CANCER 90
- 7.1.4 RISE IN PRODUCT APPROVALS 90
- 7.2 RESTRAINTS 92
- 7.2.1 POOR & LATE DIAGNOSIS OF LUNG CANCER 92
- 7.2.2 HIGH FALSE-POSITIVES AND POOR SENSITIVITY 92
- 7.3 OPPORTUNITIES 94
- 7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 94
- 7.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 94
- 7.3.3 RISING AWARENESS OF LUNG CANCER 95
- 7.4 CHALLENGES 96
- 7.4.1 STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS 96
- 7.4.2 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 96
- 7.4.3 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 97
8 GLOBAL LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 98
- 8.1 OVERVIEW 99
- 8.2 INSTRUMENTS 102
- 8.2.1 IMAGING INSTRUMENTS 103
- 8.2.1.1 CT SYSTEMS 103
- 8.2.1.2 ULTRASOUND SYSTEMS 103
- 8.2.1.3 MRI SYSTEMS 103
- 8.2.1.4 OTHERS 103
- 8.2.2 BIOPSY INSTRUMENTS 104
- 8.2.2.1 NEEDLE BIOPSY 104
- 8.2.2.2 ENDOSCOPIC BIOPSY 104
- 8.2.2.3 CORE BIOPSY 104
- 8.2.2.4 OTHERS 104
- 8.2.3 PATHOLOGY-BASED INSTRUMENTS 105
- 8.2.3.1 SLIDE STAINING SYSTEMS 105
- 8.2.3.2 TISSUE PROCESSING SYSTEMS 105
- 8.2.3.3 CELL PROCESSORS 105
- 8.2.3.4 PCR INSTRUMENTS 105
- 8.2.3.5 OTHERS PATHOLOGY-BASED INSTRUMENTS 105
- 8.3 CONSUMABLES AND ACCESSORIES 106
- 8.3.1 KITS 107
- 8.3.1.1 DNA POLYMERASE KITS 107
- 8.3.1.2 NUCLEIC ACID ISOLATION KITS 107
- 8.3.1.3 PCR KITS 107
- 8.3.1.4 OTHERS 107
- 8.3.2 REAGENTS 108
- 8.3.2.1 ASSAYS 108
- 8.3.2.2 BUFFERS 108
- 8.3.2.3 PRIMERS 108
- 8.3.2.4 OTHERS 108
- 8.3.3 PROBES 109
- 8.3.4 OTHER CONSUMABLES 109
9 GLOBAL LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE 110
- 9.1 OVERVIEW 111
- 9.2 IMAGING TEST 114
- 9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 115
- 9.2.2 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 115
- 9.2.3 CHEST X-RAY 115
- 9.2.4 BONE SCAN 115
- 9.2.5 MRI 115
- 9.2.6 OTHERS 115
- 9.3 BIOMARKERS TEST 116
- 9.3.1 EGFR MUTATION TEST 117
- 9.3.2 KRAS MUTATION TEST 117
- 9.3.3 ALK TEST 117
- 9.3.4 HER2 TEST 117
- 9.3.5 OTHERS 118
- 9.4 BIOPSY 118
- 9.4.1 NEEDLE BIOPSY 119
- 9.4.2 BRONCHOSCOPY BIOPSY 119
- 9.4.3 CORE BIOPSY 119
- 9.4.4 OTHERS 119
- 9.5 BLOOD TEST 119
- 9.5.1 COMPLETE BLOOD COUNT (CBC) 120
- 9.5.2 BLOOD CHEMISTRY TESTS 120
- 9.5.3 OTHERS 120
- 9.6 OTHERS 121
10 GLOBAL LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 122
- 10.1 OVERVIEW 123
- 10.2 NON-SMALL CELL LUNG CANCER 126
- 10.3 SMALL CELL LUNG CANCER 127
11 GLOBAL LUNG CANCER DIAGNOSTICS MARKET, BY END USER 128
- 11.1 OVERVIEW 129
- 11.2 HOSPITAL 132
- 11.3 ASSOCIATED LABS 132
- 11.4 INDEPENDENT DIAGNOSTIC LABORATORIES 133
- 11.5 DIAGNOSTIC IMAGING CENTERS 134
- 11.6 CANCER RESEARCH INSTITUTES 134
- 11.7 OTHERS 135
12 GLOBAL LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 136
- 12.1 OVERVIEW 137
- 12.2 DIRECT TENDER 140
- 12.3 RETAIL SALES 141
13 GLOBAL LUNG CANCER DIAGNOSTICS MARKET, BY REGION 142
- 13.1 OVERVIEW 143
- 13.2 NORTH AMERICA 148
- 13.2.1 U.S. 157
- 13.2.2 CANADA 162
- 13.2.3 MEXICO 167
- 13.3 EUROPE 172
- 13.3.1 GERMANY 182
- 13.3.2 U.K. 187
- 13.3.3 FRANCE 192
- 13.3.4 ITALY 197
- 13.3.5 SPAIN 202
- 13.3.6 RUSSIA 207
- 13.3.7 NETHERLANDS 212
- 13.3.8 SWITZERLAND 217
- 13.3.9 TURKEY 222
- 13.3.10 BELGIUM 227
- 13.3.11 POLAND 232
- 13.3.12 DENMARK 237
- 13.3.13 SWEDEN 242
- 13.3.14 NORWAY 247
- 13.3.15 FINLAND 252
- 13.3.16 REST OF EUROPE 257
- 13.4 ASIA-PACIFIC 258
- 13.4.1 CHINA 268
- 13.4.2 JAPAN 273
- 13.4.3 SOUTH KOREA 278
- 13.4.4 AUSTRALIA 283
- 13.4.5 INDIA 288
- 13.4.6 SINGAPORE 293
- 13.4.7 INDONESIA 298
- 13.4.8 PHILIPPINES 303
- 13.4.9 VIETNAM 308
- 13.4.10 MALAYSIA 313
- 13.4.11 THAILAND 318
- 13.4.12 NEW ZEALAND 323
- 13.4.13 TAIWAN 328
- 13.4.14 REST OF ASIA-PACIFIC 333
- 13.5 SOUTH AMERICA 334
- 13.5.1 BRAZIL 343
- 13.5.2 ARGENTINA 348
- 13.5.3 REST OF SOUTH AMERICA 353
- 13.6 MIDDLE EAST AND AFRICA 354
- 13.6.1 SOUTH AFRICA 364
- 13.6.2 EGYPT 369
- 13.6.3 SAUDI ARABIA 374
- 13.6.4 U.A.E. 379
- 13.6.5 KUWAIT 384
- 13.6.6 OMAN 389
- 13.6.7 BAHRAIN 394
- 13.6.8 QATAR 399
- 13.6.9 REST OF MIDDLE EAST AND AFRICA 404
14 GLOBAL LUNG CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 405
- 14.1 COMPANY SHARE ANALYSIS: GLOBAL 405
- 14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 406
- 14.3 COMPANY SHARE ANALYSIS: EUROPE 407
- 14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 408
15 SWOT ANALYSIS 409
16 COMPANY PROFILE 410
- 16.1 F. HOFFMANN-LA ROCHE LTD. (2022) 410
- 16.1.1 COMPANY SNAPSHOT 410
- 16.1.2 REVENUE ANALYSIS 410
- 16.1.3 COMPANY SHARE ANALYSIS 411
- 16.1.4 PRODUCT PORTFOLIO 411
- 16.1.5 RECENT DEVELOPMENTS 411
- 16.2 THERMO FISHER SCIENTIFIC INC. (2022) 412
- 16.2.1 COMPANY SNAPSHOT 412
- 16.2.2 REVENUE ANALYSIS 412
- 16.2.3 COMPANY SHARE ANALYSIS 413
- 16.2.4 PRODUCT PORTFOLIO 413
- 16.2.5 RECENT DEVELOPMENTS 413
- 16.3 ABBOTT (2022) 414
- 16.3.1 COMPANY SNAPSHOT 414
- 16.3.2 REVENUE ANALYSIS 414
- 16.3.3 COMPANY SHARE ANALYSIS 415
- 16.3.4 PRODUCT PORTFOLIO 415
- 16.3.5 RECENT DEVELOPMENTS 415
- 16.4 QUEST DIAGNOSTICS INCORPORATED (2022) 416
- 16.4.1 COMPANY SNAPSHOT 416
- 16.4.2 REVENUE ANALYSIS 416
- 16.4.3 COMPANY SHARE ANALYSIS 417
- 16.4.4 PRODUCT PORTFOLIO 417
- 16.4.5 RECENT DEVELOPMENTS 419
- 16.5 BIODESIX (2022) 420
- 16.5.1 COMPANY PROFILE 420
- 16.5.2 REVENUE ANALYSIS 420
- 16.5.3 COMPANY SHARE ANALYSIS 421
- 16.5.4 PRODUCT PORTFOLIO 421
- 16.5.5 RECENT DEVELOPMENTS 421
- 16.6 AMOY DIAGNOSTICS CO., LTD. (2022) 422
- 16.6.1 COMPANY SNAPSHOT 422
- 16.6.2 PRODUCT PORTFOLIO 422
- 16.6.3 RECENT DEVELOPMENTS 422
- 16.7 BIO-RAD LABORATORIES, INC. (2022) 423
- 16.7.1 COMPANY SNAPSHOT 423
- 16.7.2 REVENUE ANALYSIS 423
- 16.7.3 PRODUCT PORTFOLIO 424
- 16.7.4 RECENT DEVELOPMENTS 424
- 16.8 BIOCARTIS (2022) 425
- 16.8.1 COMPANY SNAPSHOT 425
- 16.8.2 REVENUE ANALYSIS 425
- 16.8.3 PRODUCT PORTFOLIO 426
- 16.8.4 RECENT DEVELOPMENTS 426
- 16.9 BODITECH MED INC. 427
- 16.9.1 COMPANY PROFILE 427
- 16.9.2 PRODUCT PORTFOLIO 427
- 16.9.3 RECENT DEVELOPMENTS 427
- 16.10 DANAHER (2022) 428
- 16.10.1 COMPANY SNAPSHOT 428
- 16.10.2 REVENUE ANALYSIS 428
- 16.10.3 PRODUCT PORTFOLIO 429
- 16.10.4 RECENT DEVELOPMENTS 429
- 16.11 DIASORIN S.P.A. (2022) 430
- 16.11.1 COMPANY SNAPSHOT 430
- 16.11.2 REVENUE ANALYSIS 430
- 16.11.3 PRODUCT PORTFOLIO 431
- 16.11.4 RECENT DEVELOPMENTS 431
- 16.12 EXACT SCIENCES UK, LTD. (SUBSIDIARY OF EXACT SCIENCE CORPORATION) (2022) 432
- 16.12.1 COMPANY SNAPSHOT 432
- 16.12.2 REVENUE ANALYSIS 432
- 16.12.3 PRODUCT PORTFOLIO 433
- 16.12.4 RECENT DEVELOPMENTS 433
- 16.13 20/20 GENE SYSTEMS 434
- 16.13.1 COMPANY PROFILE 434
- 16.13.2 PRODUCT PORTFOLIO 434
- 16.13.3 RECENT DEVELOPMENTS 434
- 16.14 GUARDANT HEALTH INC. 435
- 16.14.1 COMPANY PROFILE 435
- 16.14.2 PRODUCT PORTFOLIO 435
- 16.14.3 RECENT DEVELOPMENTS 435
- 16.15 INIVATA LTD. 436
- 16.15.1 COMPANY PROFILE 436
- 16.15.2 PRODUCT PORTFOLIO 436
- 16.15.3 RECENT DEVELOPMENTS 436